Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS207 + paclitaxel
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
JS207 + paclitaxel is a combination therapy consisting of JS207, a recombinant humanized bispecific monoclonal antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), and paclitaxel, a microtubule-stabilizing taxane chemotherapy. JS207 is designed to simultaneously block the PD-1/PD-L1 immunosuppressive pathway and inhibit VEGF-mediated angiogenesis, potentially enhancing anti-tumor activity through synergistic mechanisms. This combination is being investigated for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), particularly in patients who have failed prior platinum-based chemotherapy.
- Other names
- JS207 plus paclitaxelJS-207 plus paclitaxelJS 207 plus paclitaxel
02
Targets
BCL-2 (BCL-2 family)VEGFA (Vascular endothelial growth factor A)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on JS207 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS207 + paclitaxel.